1832 Asset Management L.P. Takes Position in Axon Enterprise, Inc. (NASDAQ:AXON)

1832 Asset Management L.P. purchased a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) during the first quarter, Holdings Channel.com reports. The institutional investor purchased 260,900 shares of the biotechnology company’s stock, valued at approximately $81,630,000.

Other large investors also recently modified their holdings of the company. Quadrature Capital Ltd acquired a new position in Axon Enterprise during the first quarter worth about $12,191,000. JT Stratford LLC acquired a new position in Axon Enterprise during the first quarter worth about $212,000. Capital International Sarl grew its holdings in Axon Enterprise by 4.3% during the first quarter. Capital International Sarl now owns 7,067 shares of the biotechnology company’s stock worth $2,211,000 after acquiring an additional 291 shares during the period. Toronto Dominion Bank grew its holdings in Axon Enterprise by 2.1% during the first quarter. Toronto Dominion Bank now owns 40,528 shares of the biotechnology company’s stock worth $12,680,000 after acquiring an additional 825 shares during the period. Finally, Advisors Asset Management Inc. grew its holdings in Axon Enterprise by 12.5% during the first quarter. Advisors Asset Management Inc. now owns 29,412 shares of the biotechnology company’s stock worth $9,202,000 after acquiring an additional 3,259 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Bank of America assumed coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a report on Thursday, April 11th. Craig Hallum boosted their price objective on Axon Enterprise from $325.00 to $370.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. William Blair restated an “outperform” rating on shares of Axon Enterprise in a report on Wednesday, April 24th. Finally, Barclays boosted their price objective on Axon Enterprise from $308.00 to $381.00 and gave the stock an “overweight” rating in a report on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $342.54.

Axon Enterprise Stock Down 0.1 %

Shares of AXON traded down $0.22 during trading hours on Friday, reaching $310.59. The company’s stock had a trading volume of 347,882 shares, compared to its average volume of 449,251. The firm has a market cap of $23.44 billion, a price-to-earnings ratio of 90.82, a P/E/G ratio of 7.00 and a beta of 0.95. Axon Enterprise, Inc. has a 1-year low of $175.37 and a 1-year high of $329.87. The company has a quick ratio of 2.55, a current ratio of 2.91 and a debt-to-equity ratio of 0.37. The company has a 50 day moving average of $294.49 and a two-hundred day moving average of $292.02.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.20. The company had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The firm’s quarterly revenue was up 34.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.51 EPS. As a group, research analysts predict that Axon Enterprise, Inc. will post 2.35 EPS for the current fiscal year.

Insider Activity at Axon Enterprise

In related news, insider Jeffrey C. Kunins sold 43,668 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $309.94, for a total value of $13,534,459.92. Following the completion of the sale, the insider now owns 189,719 shares of the company’s stock, valued at approximately $58,801,506.86. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Axon Enterprise news, President Joshua Isner sold 44,000 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $309.96, for a total transaction of $13,638,240.00. Following the completion of the sale, the president now owns 275,843 shares of the company’s stock, valued at $85,500,296.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeffrey C. Kunins sold 43,668 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $309.94, for a total value of $13,534,459.92. Following the sale, the insider now directly owns 189,719 shares of the company’s stock, valued at approximately $58,801,506.86. The disclosure for this sale can be found here. In the last quarter, insiders sold 89,447 shares of company stock valued at $27,684,677. 6.10% of the stock is owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.